{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T20:39:57Z","timestamp":1695242397853},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,12,30]],"date-time":"2016-12-30T00:00:00Z","timestamp":1483056000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00277-016-2882-9","type":"journal-article","created":{"date-parts":[[2016,12,30]],"date-time":"2016-12-30T20:33:54Z","timestamp":1483130034000},"page":"271-278","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study"],"prefix":"10.1007","volume":"96","author":[{"given":"Yael C","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsila","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Yeshurun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galit","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hila","family":"Magen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel","family":"Henig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itai","family":"Levi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liat","family":"Shargian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Trestman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uri","family":"Rouvio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Naparstek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eti","family":"Ganon-Elazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Ram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,30]]},"reference":[{"issue":"24","key":"2882_CR1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood-2012-05-423202","volume":"120","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Cavallo F (2012) Review article have drug combinations supplanted stem cell transplantation in myeloma? Blood 120(24):335\u2013341","journal-title":"Blood"},{"issue":"Supplement 7","key":"2882_CR2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/annonc\/mdn449","volume":"19","author":"J Harousseau","year":"2008","unstructured":"Harousseau J (2008) Symposium article autologous transplantation for multiple myeloma. Ann Oncol 19(Supplement 7):128\u2013133","journal-title":"Ann Oncol"},{"key":"2882_CR3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/sj.bmt.1705486","volume":"38","author":"HD Klepin","year":"2006","unstructured":"Klepin HD, Hurd DD (2006) Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions? Bone Marrow Transplant 38:585\u2013592","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"2882_CR4","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","volume":"117","author":"M Cavo","year":"2016","unstructured":"Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J et al (2016) International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 117(23):6063\u20136074","journal-title":"Blood"},{"issue":"9594","key":"2882_CR5","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","volume":"370","author":"T Facon","year":"2007","unstructured":"Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370(9594):1209\u20131218","journal-title":"Lancet"},{"issue":"4","key":"2882_CR6","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.V94.4.1248","volume":"94","author":"A Palumbo","year":"1999","unstructured":"Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C et al (1999) Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 94(4):1248\u20131253","journal-title":"Blood"},{"key":"2882_CR7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/annonc\/mdt509","volume":"25","author":"M Merz","year":"2014","unstructured":"Merz M, Neben K, Raab MS, Sauer S, Egerer G, Hundemer M et al (2014) Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann Oncol 25:189\u2013195","journal-title":"Ann Oncol"},{"key":"2882_CR8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000357394","volume":"132","author":"S Ozaki","year":"2014","unstructured":"Ozaki S, Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H et al (2014) Survival of multiple myeloma patients aged 65\u201370\u00a0years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European myeloma network. Acta Haematol 132:211\u2013219","journal-title":"Acta Haematol"},{"issue":"8","key":"2882_CR9","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2013-02-483073","volume":"122","author":"F Gay","year":"2013","unstructured":"Gay F, Magarotto V, Crippa C, Pescosta N, Guglielmelli T, Cavallo F et al (2013) Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood 122(8):1376\u20131383","journal-title":"Blood"},{"key":"2882_CR10","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau J-L, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473","journal-title":"Leukemia"},{"issue":"8354","key":"2882_CR11","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","volume":"2","author":"TJ McElwain","year":"1983","unstructured":"McElwain TJ, Powles RL (1983) High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2(8354):822\u2013824","journal-title":"Lancet"},{"issue":"12","key":"2882_CR12","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/bmt.2014.186","volume":"49","author":"PJ Shaw","year":"2014","unstructured":"Shaw PJ, Nath CE, Lazarus HM (2014) Not too little, not too much\u2014just right! ( better ways to give high dose melphalan). Bone Marrow Transplant 49(12):1457\u20131465","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2882_CR13","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.V80.7.1666.1666","volume":"80","author":"BS Jagannath","year":"1992","unstructured":"Jagannath BS, Vesole DH, Glenn L, Crowley J, Barlogie B (1992) Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 80(7):1666\u20131672","journal-title":"Blood"},{"issue":"1","key":"2882_CR14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/bmt.2015.211","volume":"51","author":"WI Bensinger","year":"2016","unstructured":"Bensinger WI, Becker PS, Gooley TA, Chauncey TR, Maloney DG, Gopal AK et al (2016) A randomized study of melphalan 200\u00a0mg\/m 2 vs. 280\u00a0mg\/m 2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant 51(1):67\u201371","journal-title":"Bone Marrow Transplant"},{"key":"2882_CR15","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.bbmt.2014.07.013","volume":"20","author":"M Sharma","year":"2014","unstructured":"Sharma M, Zhang M, Zhong X, Abidi MH, Akpek G, Bacher U et al (2014) Biology of blood and marrow transplantation older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant 20:1796\u20131803","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2882_CR16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V93.1.51","volume":"93","author":"DS Siegel","year":"1999","unstructured":"Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N et al (1999) Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 93(1):51\u201354","journal-title":"Blood"},{"issue":"5","key":"2882_CR17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/sj.bmt.1702188","volume":"25","author":"B Sirohi","year":"2000","unstructured":"Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H et al (2000) The role of autologous transplantation in patients with multiple myeloma aged 65\u00a0years and over. Bone Marrow Transplant 25(5):533\u2013539","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2882_CR18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/sj.bmt.1705360","volume":"37","author":"E Jantunen","year":"2006","unstructured":"Jantunen E, Kuittinen T, Penttila K, Lehtonen P, Mahlamaki E, Nousiainen T (2006) High-dose melphalan (200\u00a0mg\/m2) supported by autologous stem cell transplantation is safe and effective in elderly (> or = 65\u00a0years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 37(10):917\u2013922","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2882_CR19","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/sj.bmt.1705627","volume":"39","author":"MA Gertz","year":"2007","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Leung N et al (2007) Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 39(10):605\u2013611","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2882_CR20","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/ajh.21191","volume":"83","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK et al (2008) Autologous stem cell transplantation in patients of 70\u00a0years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol 83(8):614\u2013617","journal-title":"Am J Hematol"},{"issue":"1","key":"2882_CR21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5144\/1658-3876.2011.30","volume":"4","author":"J El Cheikh","year":"2011","unstructured":"El Cheikh J, Kfoury E, Calmels B, Lemarie C, Stoppa A-M, Bouabdallah R et al (2011) Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma. Hematol Oncol Stem Cell Ther 4(1):30\u201336","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"1","key":"2882_CR22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2169\/internalmedicine.52.8390","volume":"52","author":"T Muta","year":"2013","unstructured":"Muta T, Miyamoto T, Fujisaki T, Ohno Y, Kamimura T, Kato K et al (2013) Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. Intern Med 52(1):63\u201370","journal-title":"Intern Med"},{"key":"2882_CR23","doi-asserted-by":"publisher","unstructured":"Ozaki S, Shimizu K (2014) Autologous stem cell transplantation in elderly patients with multiple myeloma: past, present, and future. Biomed Res Int. doi: 10.1155\/2014\/394792","DOI":"10.1155\/2014\/394792"},{"key":"2882_CR24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/bmt.2014.255","volume":"50","author":"HW Auner","year":"2015","unstructured":"Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ et al (2015) Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant 50:209\u2013215","journal-title":"Bone Marrow Transplant"},{"key":"2882_CR25","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1200\/JCO.2013.49.0086","volume":"31","author":"P Kapoor","year":"2013","unstructured":"Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D et al (2013) Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol 31:4529\u20134535","journal-title":"J Clin Oncol"},{"key":"2882_CR26","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/cam4.257","volume":"3","author":"L Kumar","year":"2014","unstructured":"Kumar L, Iqbal N, Mookerjee A, Verma RK, Sharma OD, Batra A et al (2014) Complete response after autologous stem cell transplant in multiple myeloma. Cancer Med 3:939\u2013946","journal-title":"Cancer Med"},{"key":"2882_CR27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.clml.2013.11.009","volume":"14","author":"M Martino","year":"2014","unstructured":"Martino M, Postorino M, Gallo GA, Messina G, Neri S, Piro E et al (2014) Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs. Clin Lymphoma Myeloma Leuk 14:148\u2013154","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"34","key":"2882_CR28","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1200\/JCO.2008.21.1060","volume":"27","author":"J-L Harousseau","year":"2009","unstructured":"Harousseau J-L, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C et al (2009) Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials. J Clin Oncol 27(34):5720\u20135726","journal-title":"J Clin Oncol"},{"issue":"6","key":"2882_CR29","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3109\/10428194.2015.1121258","volume":"57","author":"YC Cohen","year":"2016","unstructured":"Cohen YC, Joffe E, Benyamini N, Dimopoulos MA, Terpos E, Trestman S et al (2016) Primary failure of bortezomib in newly diagnosed multiple myeloma\u2014understanding the magnitude, predictors, and significance. Leuk Lymphoma 57(6):1382\u20131388","journal-title":"Leuk Lymphoma"},{"key":"2882_CR30","doi-asserted-by":"crossref","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Facon T, Caillot D, Escoffre M, Arnulf B, MACRO M, Belhadj K, Garderet L, Roussel M, Mathiot C, Avet-Loiseau H, Munshi NC, Richardson PG, Anderson KC, Harousseau JL, Moreau P (2015) Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the intergroupe francophone du myelome (IFM\/DFCI 2009 trial). Blood 126(23):391","DOI":"10.1182\/blood.V126.23.391.391"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2882-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2882-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2882-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T11:21:31Z","timestamp":1601292091000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2882-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,30]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["2882"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2882-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,30]]}}}